Description: BrightGene Bio-Medical Technology Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of medicines, and generic APIs and FDFs in China. Its product pipeline includes immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, and novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis. The company also develops Eribulin, Trabectedin, Fondaparinux, Caspofungin, and non-biological molecules; macromolecules, such as Ferumoxytol and Ferric pyrophosphate citrate; and ADC cytotoxic payloads comprising Maytansinoids, Auristatins, and Calicheamicin. It offers cardiovascular, antibacterial, ADC, oncology, antifungal, iron supplement, anti-HBV, veterinary, and immuno products. The company was founded in 2001 and is based in Suzhou, China.
Home Page: www.bright-gene.com
Building C25-28
Suzhou,
215123
China
Phone:
86 512 6262 0988
Officers
| Name | Title |
|---|---|
| Mr. Jiandong Yuan | Chairman & GM |
Exchange: SHG
Country: CN : China
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 37.4 |
| Price-to-Book MRQ: | 4.7572 |
| Price-to-Sales TTM: | 8.9181 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 910 |